Avalo Therapeutics vs Celldex Therapeutics
AVTX and CLDX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AVTX and CLDX compare
Celldex Therapeutics is the larger company, worth 5.4 times as much as Avalo Therapeutics ($2.3B against $416M).
Avalo Therapeutics scores higher on the StockData Score (8 against 7 for Celldex Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AVTX | CLDX |
|---|---|---|
| Size and price | ||
| Market cap | $416M | $2.3B |
| Share price | $7.76 | $28.83 |
| Change, 1 year | −49.7% | 18.9% |
| Change, 5 years | −99.9% | −32.9% |
| Beta (5Y) | 0.87 | 1.32 |
| Employees | 23 | 198 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 0 | 0 |
| Performance score | 1 | 1 |
| Health score | 6 | 6 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 14329× |
| P/B | 1.0× (better) | 3.5× |
| FCF yield | – | −11.5% |
| Growth | ||
| Revenue growth (TTM) | – | −93.9% |
| Revenue growth, 5Y average | −61.2% | −26.9% (better) |
| Profitability | ||
| Operating margin | – | −211685% |
| Net margin | – | −195609% |
| FCF margin | – | −164392% |
| Return on equity | −33.6% (better) | −49.5% |
| Return on invested capital | – | −3698% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 16.63 (better) | 10.97 |
| Altman Z-score | 4.32 | 14.36 (better) |
| Piotroski F-score | 2 | 2 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 135% | 109% |
| Held by insiders | 0.71% | 0.41% |
| Insider net buying, 12 months | −$8.3M | −$121K (better) |
| Short interest, % of float | 16.7% | 12.7% |
Go deeper
- AVTX stock overview
- AVTX income statement
- AVTX valuation and score
- CLDX stock overview
- CLDX income statement
- CLDX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.